[
  {
    "ts": null,
    "headline": "Podcast: U.S. Stocks Slip as Israel-Iran Conflict Continues",
    "summary": "President Trump called for Iran’s unconditional surrender and said he wouldn’t target the country’s leader “for now.” Plus: Verve Therapeutics shares soar after Eli Lilly agrees to acquire the gene-editing company.",
    "url": "https://finnhub.io/api/news?id=606830608a7f84925d68215af03c96858c01ed7845348270575ccf11af1e3981",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750196970,
      "headline": "Podcast: U.S. Stocks Slip as Israel-Iran Conflict Continues",
      "id": 135340738,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump called for Iran’s unconditional surrender and said he wouldn’t target the country’s leader “for now.” Plus: Verve Therapeutics shares soar after Eli Lilly agrees to acquire the gene-editing company.",
      "url": "https://finnhub.io/api/news?id=606830608a7f84925d68215af03c96858c01ed7845348270575ccf11af1e3981"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More",
    "summary": "Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028.",
    "url": "https://finnhub.io/api/news?id=e0cdfabb92b8794602b1585ee90fe7d22cd290315f6dc7a154156599d3473407",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750192440,
      "headline": "These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More",
      "id": 135340275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028.",
      "url": "https://finnhub.io/api/news?id=e0cdfabb92b8794602b1585ee90fe7d22cd290315f6dc7a154156599d3473407"
    }
  },
  {
    "ts": null,
    "headline": "Solar stocks, Eli Lilly & Verve, PureCycle: Trending Tickers",
    "summary": "Enphase (ENPH), SolarEdge (SEDG), First Solar (FSLR), Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President Trump's tax bill, which included cuts to solar and wind energy tax credits. Eli Lilly (LLY) is set to acquire Verve Therapeutics (VERV), sending Verve's stock skyrocketing. PureCycle Technologies (PCT) stock surges on the company's plans to grow its plastic recycling capacity to 1 billion pounds by 2030. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=a73dca4e683de20dead46762d88fcf320b48bdd8fadf223fd452e2db540d50f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750190394,
      "headline": "Solar stocks, Eli Lilly & Verve, PureCycle: Trending Tickers",
      "id": 135340496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Enphase (ENPH), SolarEdge (SEDG), First Solar (FSLR), Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President Trump's tax bill, which included cuts to solar and wind energy tax credits. Eli Lilly (LLY) is set to acquire Verve Therapeutics (VERV), sending Verve's stock skyrocketing. PureCycle Technologies (PCT) stock surges on the company's plans to grow its plastic recycling capacity to 1 billion pounds by 2030. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=a73dca4e683de20dead46762d88fcf320b48bdd8fadf223fd452e2db540d50f6"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
    "summary": "Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and",
    "url": "https://finnhub.io/api/news?id=b3b9768ed5f813f95bc11d2a80db8578df0f20b3971a2af3afa621f9773bb9ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750190036,
      "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
      "id": 135340427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and",
      "url": "https://finnhub.io/api/news?id=b3b9768ed5f813f95bc11d2a80db8578df0f20b3971a2af3afa621f9773bb9ae"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn",
    "summary": "Eli Lilly’s buyout of the genetic medicine developer adds to lofty big pharma spending in 2025.",
    "url": "https://finnhub.io/api/news?id=0170aca4b7ae4a738fcb61283e878726a9afd1358d32b38778bd3a05dd152b80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750181283,
      "headline": "Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn",
      "id": 135336537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s buyout of the genetic medicine developer adds to lofty big pharma spending in 2025.",
      "url": "https://finnhub.io/api/news?id=0170aca4b7ae4a738fcb61283e878726a9afd1358d32b38778bd3a05dd152b80"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Eyes US$1.3 Billion Acquisition Of Verve Therapeutics",
    "summary": "Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by significant events such as its advanced negotiations to acquire gene editing startup Verve Therapeutics for up to $1.3 billion. This acquisition aligns with Lilly's focus on expanding its pipeline of experimental medicines. Additionally, the company engaged in a global partnership with Juvena Therapeutics, which could further enhance its portfolio. Despite broader market...",
    "url": "https://finnhub.io/api/news?id=4d4487cc3713fd0e4a7165079ad49eed50a0c978c4f9cb217109ab4910627781",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750180650,
      "headline": "Eli Lilly (NYSE:LLY) Eyes US$1.3 Billion Acquisition Of Verve Therapeutics",
      "id": 135336538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by significant events such as its advanced negotiations to acquire gene editing startup Verve Therapeutics for up to $1.3 billion. This acquisition aligns with Lilly's focus on expanding its pipeline of experimental medicines. Additionally, the company engaged in a global partnership with Juvena Therapeutics, which could further enhance its portfolio. Despite broader market...",
      "url": "https://finnhub.io/api/news?id=4d4487cc3713fd0e4a7165079ad49eed50a0c978c4f9cb217109ab4910627781"
    }
  },
  {
    "ts": null,
    "headline": "Indexes end lower as Israel-Iran fighting raises investor anxiety",
    "summary": "U.S. stocks finished withlosses on Tuesday as the Israel-Iran conflict raged on for afifth day and kept investor anxiety high, with the U.S. militarymoving fighter jets to the Middle East. ...",
    "url": "https://finnhub.io/api/news?id=f6fbfebc414e881966c0a0e8a7d5eb5b864618daa0cbb73e15b4308bd1cc904d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750180153,
      "headline": "Indexes end lower as Israel-Iran fighting raises investor anxiety",
      "id": 135339602,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. stocks finished withlosses on Tuesday as the Israel-Iran conflict raged on for afifth day and kept investor anxiety high, with the U.S. militarymoving fighter jets to the Middle East. ...",
      "url": "https://finnhub.io/api/news?id=f6fbfebc414e881966c0a0e8a7d5eb5b864618daa0cbb73e15b4308bd1cc904d"
    }
  },
  {
    "ts": null,
    "headline": "WeightWatchers to exit process to cut $1.15 billion debt next week",
    "summary": "WW International,formerly known as WeightWatchers, is on track to exit itsfinancial reorganization to cut $1.15 billion in debt next weekas part of its bankruptcy process, the weight management...",
    "url": "https://finnhub.io/api/news?id=5dbb2a331f49c8c25424320e72ef1710f07ef2b50d523963809b9c306e942571",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750176850,
      "headline": "WeightWatchers to exit process to cut $1.15 billion debt next week",
      "id": 135339341,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "WW International,formerly known as WeightWatchers, is on track to exit itsfinancial reorganization to cut $1.15 billion in debt next weekas part of its bankruptcy process, the weight management...",
      "url": "https://finnhub.io/api/news?id=5dbb2a331f49c8c25424320e72ef1710f07ef2b50d523963809b9c306e942571"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly",
    "summary": "VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.",
    "url": "https://finnhub.io/api/news?id=93eb80604315048ad74bb5486dbd182a144eafbd2e1963f10eddd4e80649ee94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750176720,
      "headline": "Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly",
      "id": 135336539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.",
      "url": "https://finnhub.io/api/news?id=93eb80604315048ad74bb5486dbd182a144eafbd2e1963f10eddd4e80649ee94"
    }
  },
  {
    "ts": null,
    "headline": "Indexes end lower as conflict between Israel and Iran adds caution",
    "summary": "U.S. stocks ended lower onTuesday as the Israel-Iran conflict raged on for a fifth day andkept investor anxiety high, with the U.S. military movingfighter jets to the Middle East. ...",
    "url": "https://finnhub.io/api/news?id=e49fabccd5682419235cef22e116d192c14cb8dd09ca56c6783655a6da6b3213",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750176069,
      "headline": "Indexes end lower as conflict between Israel and Iran adds caution",
      "id": 135339256,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. stocks ended lower onTuesday as the Israel-Iran conflict raged on for a fifth day andkept investor anxiety high, with the U.S. military movingfighter jets to the Middle East. ...",
      "url": "https://finnhub.io/api/news?id=e49fabccd5682419235cef22e116d192c14cb8dd09ca56c6783655a6da6b3213"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May",
    "summary": "Eli Lilly (LLY) said Tuesday it has agreed to acquire Verve Therapeutics (VERV) for up to $1.3 billi",
    "url": "https://finnhub.io/api/news?id=738bb479de9b47cdb49e4aa75396cddcd65a63230e20b019c1d88e17e7257483",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750175436,
      "headline": "Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May",
      "id": 135333153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Tuesday it has agreed to acquire Verve Therapeutics (VERV) for up to $1.3 billi",
      "url": "https://finnhub.io/api/news?id=738bb479de9b47cdb49e4aa75396cddcd65a63230e20b019c1d88e17e7257483"
    }
  },
  {
    "ts": null,
    "headline": "Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program",
    "summary": "Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program",
    "url": "https://finnhub.io/api/news?id=3dba68fc293deeeddc80c22f8dc8560da2814254d74136de1876a25bb2665bad",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750174926,
      "headline": "Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program",
      "id": 135339194,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3dba68fc293deeeddc80c22f8dc8560da2814254d74136de1876a25bb2665bad"
    }
  },
  {
    "ts": null,
    "headline": "Madison Sustainable Equity SMA Q1 2025 Investment Strategy Letter",
    "summary": "The first quarter saw the S&P 500 deliver a total return of -4.3%, largely driven by a -5.6% decline in March. Read more here.",
    "url": "https://finnhub.io/api/news?id=67bfe387131cc2bd9265dd8fa8b50b840739aa7c0bbd2e15e8e5186106f9124a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750174200,
      "headline": "Madison Sustainable Equity SMA Q1 2025 Investment Strategy Letter",
      "id": 135339033,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311959502/image_1311959502.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The first quarter saw the S&P 500 deliver a total return of -4.3%, largely driven by a -5.6% decline in March. Read more here.",
      "url": "https://finnhub.io/api/news?id=67bfe387131cc2bd9265dd8fa8b50b840739aa7c0bbd2e15e8e5186106f9124a"
    }
  },
  {
    "ts": null,
    "headline": "AMD extends gains, solar stocks plummet, pharma stocks",
    "summary": "Wealth host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute. Advanced Micro Devices (AMD) stock extends its gains from Monday when Piper Sandler raised its price target for the company. Solar energy stocks, including Enphase (ENPH), First Solar (FSLR), and SolarEdge (SEDG), plummet as Senate Republicans consider phasing out clean energy tax credits by 2028. Pharmaceutical stocks, such as Eli Lilly (LLY), Pfizer (PFE), and Abbvie (ABBV), are under pressure as the Trump administration considers curbing direct-to-consumer drug advertising. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=90631f694600db52342c8cb957af406f7d9a2700e514e3f3adc13df2cf440585",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750173499,
      "headline": "AMD extends gains, solar stocks plummet, pharma stocks",
      "id": 135327762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wealth host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute. Advanced Micro Devices (AMD) stock extends its gains from Monday when Piper Sandler raised its price target for the company. Solar energy stocks, including Enphase (ENPH), First Solar (FSLR), and SolarEdge (SEDG), plummet as Senate Republicans consider phasing out clean energy tax credits by 2028. Pharmaceutical stocks, such as Eli Lilly (LLY), Pfizer (PFE), and Abbvie (ABBV), are under pressure as the Trump administration considers curbing direct-to-consumer drug advertising. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=90631f694600db52342c8cb957af406f7d9a2700e514e3f3adc13df2cf440585"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion",
    "summary": "Tender offer at $10.50 plus potential $3.00 CVR underscores AGTC's strategic pivot",
    "url": "https://finnhub.io/api/news?id=0ad5f372841a73ee4886055dc107b42fbdfd5b30076de869326e5fd4a2470c01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750172934,
      "headline": "Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion",
      "id": 135327947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tender offer at $10.50 plus potential $3.00 CVR underscores AGTC's strategic pivot",
      "url": "https://finnhub.io/api/news?id=0ad5f372841a73ee4886055dc107b42fbdfd5b30076de869326e5fd4a2470c01"
    }
  },
  {
    "ts": null,
    "headline": "Why Verve Therapeutics Stock Is Skyrocketing Today",
    "summary": "Eli Lilly plans to acquire Verve for up to $1.3 billion.  Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday.  Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a \"definitive agreement for Lilly to acquire Verve.\"",
    "url": "https://finnhub.io/api/news?id=668dbe0340bf7db518b1f4ae4b45a06c4d77979e1f171f60ccef187000686ddc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750172759,
      "headline": "Why Verve Therapeutics Stock Is Skyrocketing Today",
      "id": 135327948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly plans to acquire Verve for up to $1.3 billion.  Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday.  Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a \"definitive agreement for Lilly to acquire Verve.\"",
      "url": "https://finnhub.io/api/news?id=668dbe0340bf7db518b1f4ae4b45a06c4d77979e1f171f60ccef187000686ddc"
    }
  },
  {
    "ts": null,
    "headline": "Indexes fall as conflict between Israel and Iran intensifies",
    "summary": "U.S. stocks were lower onTuesday, with indexes adding to losses in afternoon trading asthe Israel-Iran conflict raged on for a fifth day, with the U.S.military moving fighter jets to the Middle...",
    "url": "https://finnhub.io/api/news?id=e16565658abf6597e4b71a2286a824437f737e273aeb4e7b36d32aa5c64beb44",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750171932,
      "headline": "Indexes fall as conflict between Israel and Iran intensifies",
      "id": 135338098,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. stocks were lower onTuesday, with indexes adding to losses in afternoon trading asthe Israel-Iran conflict raged on for a fifth day, with the U.S.military moving fighter jets to the Middle...",
      "url": "https://finnhub.io/api/news?id=e16565658abf6597e4b71a2286a824437f737e273aeb4e7b36d32aa5c64beb44"
    }
  },
  {
    "ts": null,
    "headline": "This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly",
    "summary": "This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly",
    "url": "https://finnhub.io/api/news?id=ac2ad5859f4ca268cd4e4079199e0378d8050c68c4b2185979b87f2c2358cc5d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750169760,
      "headline": "This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly",
      "id": 135354321,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly",
      "url": "https://finnhub.io/api/news?id=ac2ad5859f4ca268cd4e4079199e0378d8050c68c4b2185979b87f2c2358cc5d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.",
    "summary": "Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.",
    "url": "https://finnhub.io/api/news?id=b4a22f11de4affb6aeca933712941a01d56b2217b47b177b9761ab606fe48456",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750168920,
      "headline": "Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.",
      "id": 135327949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.",
      "url": "https://finnhub.io/api/news?id=b4a22f11de4affb6aeca933712941a01d56b2217b47b177b9761ab606fe48456"
    }
  },
  {
    "ts": null,
    "headline": "T-Mobile & Softbank, solar, Eli Lilly & Verve: Trending Tickers",
    "summary": "Softbank (SFTBF) sold more than 21 million T-Mobile (TMUS) shares to fund its artificial intelligence (AI) efforts, according to reports from Bloomberg. Solar stocks, like Sunrun (RUN), SolarEdge (SEDG), and First Solar (FSLR), are plummeting as solar tax credits are on the chopping block during the Senate's tax bill revisions. Eli Lilly (LLY) announces it will acquire Verve Therapeutics (VERV) in a $1.3 billion deal expected to close in the third quarter of this year. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=d224177bfdd1612748301dd38db410d9047dbe8a2d18eac778e2b86840a12ec7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750168423,
      "headline": "T-Mobile & Softbank, solar, Eli Lilly & Verve: Trending Tickers",
      "id": 135327103,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Softbank (SFTBF) sold more than 21 million T-Mobile (TMUS) shares to fund its artificial intelligence (AI) efforts, according to reports from Bloomberg. Solar stocks, like Sunrun (RUN), SolarEdge (SEDG), and First Solar (FSLR), are plummeting as solar tax credits are on the chopping block during the Senate's tax bill revisions. Eli Lilly (LLY) announces it will acquire Verve Therapeutics (VERV) in a $1.3 billion deal expected to close in the third quarter of this year. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=d224177bfdd1612748301dd38db410d9047dbe8a2d18eac778e2b86840a12ec7"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, T-Mobile, Lennar, and More",
    "summary": "Solar stocks tumble as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028.",
    "url": "https://finnhub.io/api/news?id=59e5581ce32588c19e36df2391c4f545b332471e2146b00fdc678be7db19b05e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750159680,
      "headline": "These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, T-Mobile, Lennar, and More",
      "id": 135326112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Solar stocks tumble as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028.",
      "url": "https://finnhub.io/api/news?id=59e5581ce32588c19e36df2391c4f545b332471e2146b00fdc678be7db19b05e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol",
    "summary": "Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment. Read more on my thoughts on this deal.",
    "url": "https://finnhub.io/api/news?id=652b434cd20093851a655c762976c0c071b54e966c30f746cdbda5f2629ecccb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750167013,
      "headline": "Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol",
      "id": 135334032,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150929165/image_2150929165.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment. Read more on my thoughts on this deal.",
      "url": "https://finnhub.io/api/news?id=652b434cd20093851a655c762976c0c071b54e966c30f746cdbda5f2629ecccb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Strikes up to $1.3 Billion Deal to Buy Verve Therapeutics",
    "summary": "Eli Lilly (LLY) has agreed to acquire Verve Therapeutics (VERV) in a deal worth up to $1.3 billion,",
    "url": "https://finnhub.io/api/news?id=e13cd47b2f0eb7ef309913cd5c7ad2de68b68f9cd42b9c5a9602a988bff558af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750166091,
      "headline": "Eli Lilly Strikes up to $1.3 Billion Deal to Buy Verve Therapeutics",
      "id": 135327952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has agreed to acquire Verve Therapeutics (VERV) in a deal worth up to $1.3 billion,",
      "url": "https://finnhub.io/api/news?id=e13cd47b2f0eb7ef309913cd5c7ad2de68b68f9cd42b9c5a9602a988bff558af"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover",
    "summary": "Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.",
    "url": "https://finnhub.io/api/news?id=e87a13020c8421c0a00c63523902c62c950d416f45bd309a7d3fa45918a49ab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750166067,
      "headline": "Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover",
      "id": 135327185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.",
      "url": "https://finnhub.io/api/news?id=e87a13020c8421c0a00c63523902c62c950d416f45bd309a7d3fa45918a49ab0"
    }
  },
  {
    "ts": null,
    "headline": "Fed Policy-Setting Meeting Begins as US Equity Futures Decline Pre-Bell",
    "summary": "US equity futures were down before Tuesday's opening bell as the Federal Reserve begins its meeting",
    "url": "https://finnhub.io/api/news?id=9c99d1fb32c933b5eaeccc18849c6532dffdc6ca751b46e8e8b0ea2db3af35ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750165656,
      "headline": "Fed Policy-Setting Meeting Begins as US Equity Futures Decline Pre-Bell",
      "id": 135327767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity futures were down before Tuesday's opening bell as the Federal Reserve begins its meeting",
      "url": "https://finnhub.io/api/news?id=9c99d1fb32c933b5eaeccc18849c6532dffdc6ca751b46e8e8b0ea2db3af35ef"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)",
    "summary": "Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.",
    "url": "https://finnhub.io/api/news?id=2cff764c626308adf056c7aa82af9e200b0629bf1eba4132f999b0636f748406",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750164679,
      "headline": "Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)",
      "id": 135331111,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193239681/image_2193239681.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.",
      "url": "https://finnhub.io/api/news?id=2cff764c626308adf056c7aa82af9e200b0629bf1eba4132f999b0636f748406"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B",
    "summary": "Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.",
    "url": "https://finnhub.io/api/news?id=b9fd28a4203ad34b338234a3ac7cca3deeccdd7dd7a29912dc9cfb91bec54a48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750162450,
      "headline": "Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B",
      "id": 135327955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.",
      "url": "https://finnhub.io/api/news?id=b9fd28a4203ad34b338234a3ac7cca3deeccdd7dd7a29912dc9cfb91bec54a48"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Escalating Iran-Israel Conflict",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr",
    "url": "https://finnhub.io/api/news?id=54be4607688dfea523f0d7198203e612bde6b789d4d1af0c299fdebe938055c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750162432,
      "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Escalating Iran-Israel Conflict",
      "id": 135326561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr",
      "url": "https://finnhub.io/api/news?id=54be4607688dfea523f0d7198203e612bde6b789d4d1af0c299fdebe938055c3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion",
    "summary": "Eli Lilly  agreed to acquire  Verve Therapeutics  for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.  Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.50 each, the companies said.  Lilly said Tuesday it could pay up to another $300 million for Verve, contingent on the company’s lead treatment achieving certain clinical milestones.",
    "url": "https://finnhub.io/api/news?id=33c0795d350d2273ca3b9d62938941cb873d6c81c412eee629ed5e95a8fbadf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750161300,
      "headline": "Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion",
      "id": 135327957,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  agreed to acquire  Verve Therapeutics  for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.  Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.50 each, the companies said.  Lilly said Tuesday it could pay up to another $300 million for Verve, contingent on the company’s lead treatment achieving certain clinical milestones.",
      "url": "https://finnhub.io/api/news?id=33c0795d350d2273ca3b9d62938941cb873d6c81c412eee629ed5e95a8fbadf5"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks That May Be Trading Below Their Estimated Value",
    "summary": "Over the last 7 days, the United States market has remained flat, yet it is up 11% over the past year with earnings forecasted to grow by 14% annually. In this context of steady growth and optimistic earnings forecasts, identifying stocks that may be trading below their estimated value can offer investors opportunities for potential gains.",
    "url": "https://finnhub.io/api/news?id=4ddd193a240629ce5ce2d0eafad7aedeb65a0f94fd73eb1e5cda60427bfc8341",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750160274,
      "headline": "3 Stocks That May Be Trading Below Their Estimated Value",
      "id": 135327575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Over the last 7 days, the United States market has remained flat, yet it is up 11% over the past year with earnings forecasted to grow by 14% annually. In this context of steady growth and optimistic earnings forecasts, identifying stocks that may be trading below their estimated value can offer investors opportunities for potential gains.",
      "url": "https://finnhub.io/api/news?id=4ddd193a240629ce5ce2d0eafad7aedeb65a0f94fd73eb1e5cda60427bfc8341"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to acquire Verve in $1B bet on gene editing for heart disease",
    "summary": "The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong in decline in Verve’s share price amid skepticism over the need for such a therapy.",
    "url": "https://finnhub.io/api/news?id=25565d1fe66d9c08a009ca2897b20f90680b7d3e87c3a0fce7121daa072298ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750158360,
      "headline": "Lilly to acquire Verve in $1B bet on gene editing for heart disease",
      "id": 135328555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong in decline in Verve’s share price amid skepticism over the need for such a therapy.",
      "url": "https://finnhub.io/api/news?id=25565d1fe66d9c08a009ca2897b20f90680b7d3e87c3a0fce7121daa072298ce"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve.",
    "url": "https://finnhub.io/api/news?id=721994f37f54ae5b1d95376a60845db7884331295c51a121318f9bf961849f32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750157100,
      "headline": "Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk",
      "id": 135327959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve.",
      "url": "https://finnhub.io/api/news?id=721994f37f54ae5b1d95376a60845db7884331295c51a121318f9bf961849f32"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Eli Lilly Nears $1.3 Billion Acquisition of Gene-Editing Biotech Verve Therapeutics",
    "summary": "Eli Lilly (LLY) is in advanced talks to acquire gene-editing biotech Verve Therapeutics (VERV) for u",
    "url": "https://finnhub.io/api/news?id=7710672915fee0b50e4442186659294e1a59e66b7b4177e2bbfce307234dd191",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750154143,
      "headline": "Market Chatter: Eli Lilly Nears $1.3 Billion Acquisition of Gene-Editing Biotech Verve Therapeutics",
      "id": 135327960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is in advanced talks to acquire gene-editing biotech Verve Therapeutics (VERV) for u",
      "url": "https://finnhub.io/api/news?id=7710672915fee0b50e4442186659294e1a59e66b7b4177e2bbfce307234dd191"
    }
  },
  {
    "ts": null,
    "headline": "Deals of the day-Mergers and acquisitions",
    "summary": "The following bids, mergers,acquisitions and disposals were reported by 1330 GMT on Tuesday: ** Surgery Partners said it was unable to agree to the terms set by...",
    "url": "https://finnhub.io/api/news?id=d5a50a4bc8d592ab3e8983ad2ba5f4041af1e5934e79bee78320900bc3ad856c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750153036,
      "headline": "Deals of the day-Mergers and acquisitions",
      "id": 135326789,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The following bids, mergers,acquisitions and disposals were reported by 1330 GMT on Tuesday: ** Surgery Partners said it was unable to agree to the terms set by...",
      "url": "https://finnhub.io/api/news?id=d5a50a4bc8d592ab3e8983ad2ba5f4041af1e5934e79bee78320900bc3ad856c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)",
    "summary": "Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)",
    "url": "https://finnhub.io/api/news?id=3b4ae69a1872e683f9ef526b3493e7bc77b42cda00af870274610b700d5758c2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750149994,
      "headline": "Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)",
      "id": 135326309,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3b4ae69a1872e683f9ef526b3493e7bc77b42cda00af870274610b700d5758c2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: acquires Verve Therapeutics",
    "summary": "US laboratory Eli Lilly announced on Tuesday that it would acquire Verve Therapeutics for up to $1.3bn to strengthen its portfolio of cardiovascular disease treatments.The offer from the...",
    "url": "https://finnhub.io/api/news?id=f993de2c54ee68412b29d182e881579dbb6cee3df1486f0a32fc80d9a5a23bfb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750149544,
      "headline": "Eli Lilly: acquires Verve Therapeutics",
      "id": 135326224,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "US laboratory Eli Lilly announced on Tuesday that it would acquire Verve Therapeutics for up to $1.3bn to strengthen its portfolio of cardiovascular disease treatments.The offer from the...",
      "url": "https://finnhub.io/api/news?id=f993de2c54ee68412b29d182e881579dbb6cee3df1486f0a32fc80d9a5a23bfb"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to offer all approved doses of Zepbound single-dose vials through LillyDirect Self Pay Pharmacy Solutions",
    "summary": "INDIANAPOLIS - Eli Lilly and Company announced that the highest approved doses of Zepbound -12.5 mg and 15 mg-will soon be available in single-dose vials for $499 per month through LillyDirect's Self...",
    "url": "https://finnhub.io/api/news?id=6f79993bc5d293486218456856bda2e68f932af051eef5ecadc22799104d4708",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750147404,
      "headline": "Lilly to offer all approved doses of Zepbound single-dose vials through LillyDirect Self Pay Pharmacy Solutions",
      "id": 135325879,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company announced that the highest approved doses of Zepbound -12.5 mg and 15 mg-will soon be available in single-dose vials for $499 per month through LillyDirect's Self...",
      "url": "https://finnhub.io/api/news?id=6f79993bc5d293486218456856bda2e68f932af051eef5ecadc22799104d4708"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street futures dip as Mideast conflict continues",
    "summary": "U.S. stock index futures slipped onTuesday as the Israel-Iran conflict entered its fifth day,dampening global investor confidence ahead of the FederalReserve's upcoming monetary policy decision. ...",
    "url": "https://finnhub.io/api/news?id=25b976d2e90a45be0089c15dc5797750b1c596eb6aab5cc761860d2dd606b0eb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750146040,
      "headline": "Wall Street futures dip as Mideast conflict continues",
      "id": 135325688,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. stock index futures slipped onTuesday as the Israel-Iran conflict entered its fifth day,dampening global investor confidence ahead of the FederalReserve's upcoming monetary policy decision. ...",
      "url": "https://finnhub.io/api/news?id=25b976d2e90a45be0089c15dc5797750b1c596eb6aab5cc761860d2dd606b0eb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say",
    "summary": "Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. ...",
    "url": "https://finnhub.io/api/news?id=e6845bd8c572d004d153258c05ac13baca2781bef46e14233b91222ad23cc7e6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750143309,
      "headline": "Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say",
      "id": 135325334,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. ...",
      "url": "https://finnhub.io/api/news?id=e6845bd8c572d004d153258c05ac13baca2781bef46e14233b91222ad23cc7e6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization […]",
    "url": "https://finnhub.io/api/news?id=a9cd4fcade1bb518aafc621f53361d6055f36a1edd5c5f4b1246490ff7c8f0a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750141426,
      "headline": "Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform",
      "id": 135317644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization […]",
      "url": "https://finnhub.io/api/news?id=a9cd4fcade1bb518aafc621f53361d6055f36a1edd5c5f4b1246490ff7c8f0a8"
    }
  },
  {
    "ts": null,
    "headline": "Green energy stocks stumble, and other early market movers",
    "summary": "Green energy stocks stumble, and other early market movers",
    "url": "https://finnhub.io/api/news?id=7c294b706069e51c54424d110ff4506c2f4ffadbebd590c79ea51cd9232e0dfd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750139664,
      "headline": "Green energy stocks stumble, and other early market movers",
      "id": 135329337,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Green energy stocks stumble, and other early market movers",
      "url": "https://finnhub.io/api/news?id=7c294b706069e51c54424d110ff4506c2f4ffadbebd590c79ea51cd9232e0dfd"
    }
  },
  {
    "ts": null,
    "headline": "Impax U.S. Sustainable Economy Fund Q1 2025 Commentary",
    "summary": "The Impax US Sustainable Economy Fund underperformed the Russell 1000 benchmark in the first quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=23bf52ec80349eb550b8386c0e65d9677b0d05d4d0653f2de803d342d61fd5fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750134720,
      "headline": "Impax U.S. Sustainable Economy Fund Q1 2025 Commentary",
      "id": 135322264,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161001170/image_2161001170.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Impax US Sustainable Economy Fund underperformed the Russell 1000 benchmark in the first quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=23bf52ec80349eb550b8386c0e65d9677b0d05d4d0653f2de803d342d61fd5fd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story",
    "summary": "Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong. The company’s underlying business is thriving, with analysts projecting its market value could hit $1 trillion in the coming years. Positive developments from its drug pipeline are boosting investor confidence, as promising clinical data could […]",
    "url": "https://finnhub.io/api/news?id=a8a8c3edce8d722833dde1997614b09023f0a869f3561183c7d53559d4e8cca2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750133917,
      "headline": "Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story",
      "id": 135313674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong. The company’s underlying business is thriving, with analysts projecting its market value could hit $1 trillion in the coming years. Positive developments from its drug pipeline are boosting investor confidence, as promising clinical data could […]",
      "url": "https://finnhub.io/api/news?id=a8a8c3edce8d722833dde1997614b09023f0a869f3561183c7d53559d4e8cca2"
    }
  }
]